ArticleBlood advances2026

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Andrew H Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.